Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
99 studies found for:    "Neisseria meningitidis"
Show Display Options
Rank Status Study
1 Completed Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)
Condition: Neisseria Meningitidis
Intervention: Biological: MenBvac
2 Completed Neisseria Meningitidis Burden of Disease Study
Conditions: Streptococcus Pneumoniae;   Neisseria Meningitidis;   Haemophilus Influenzae
Interventions: Other: Data collection;   Other: CSF samples testing
3 Recruiting Evaluation of Vaccinal and Natural Immunity Against Meningococcus C
Condition: Prevention of Meningococcus C Infections
Intervention: Other: Meningococcus C conjugate vaccine
4 Completed NeisVac-C Single Prime Study in Infants
Condition: Neisseria Meningitidis
Interventions: Biological: Meningococcal group C polysaccharide conjugate vaccine;   Biological: Pneumococcal 13-valent conjugate vaccine;   Biological: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
5 Completed Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
Condition: Neisseria Meningitidis
Intervention: Biological: Meningococcal outer membrane vesicle vaccine "MenBVac"
6 Completed Meningococcal B Vaccination in University Students
Condition: Neisseria Meningitidis Serogroup B
Intervention: Biological: Meningococcal B Vaccine NZ
7 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
8 Completed N. Meningitidis Carriage Study
Condition: Infections, Meningococcal
Interventions: Procedure: Posterior pharyngeal swab;   Other: Data collection
9 Completed
Has Results
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: Hib-MenCY-TT vaccine;   Biological: Hib-MenC-TT vaccine;   Biological: Menjugate ®;   Biological: Infanrix penta ®;   Biological: Infanrix hexa ®
10 Completed
Has Results
Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: Hib-MenCY-TT vaccine (MenHibrix);   Biological: Meningitec®;   Biological: ActHIB®;   Biological: Infanrix® Penta;   Biological: Prevenar®;   Biological: Mencevax® ACWY;   Biological: PRP (Polyribosyl Ribitol Phosphate)
11 Completed
Has Results
Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: MenHibrix (Hib-MenCY-TT);   Biological: Infanrix® Penta;   Biological: Prevenar®;   Biological: ActHIB®;   Biological: Meningitec®;   Biological: M-M-R®II;   Biological: Varivax®;   Biological: PedvaxHIB®
12 Recruiting Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
Condition: Meningococcal B Disease
Interventions: Biological: rLP2086 vaccine;   Biological: Pediatric HAV vaccine
13 Active, not recruiting A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
Condition: MENINGOCOCCAL INFECTION
Interventions: Biological: Bivalent rLP2086 Vaccine;   Biological: Licensed pediatric hepatits A vaccine;   Other: Normal Saline
14 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014);   Biological: PedvaxHIB;   Biological: Prevnar;   Biological: M-M-R II;   Biological: Varivax
15 Completed Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: Hib-MenCY-TT vaccine (GSK792014);   Biological: Pediarix®;   Biological: Rotarix®;   Biological: Prevnar 13®;   Biological: PedvaxHIB®;   Biological: Havrix®
16 Completed
Has Results
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: MenitorixTM;   Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: PrevenarTM;   Biological: MeningitecTM;   Biological: NeisVac-CTM;   Biological: InfanrixTM hexa;   Biological: InfanrixTM penta;   Biological: InfanrixTM IPV/Hib;   Biological: InfanrixTM IPV
17 Completed
Has Results
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: GSK2197870A;   Biological: Prevenar™;   Biological: Menitorix™;   Biological: Pediacel™;   Biological: Menjugate™
18 Completed
Has Results
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
Conditions: Neisseria Meningitidis;   Meningococcal Infections
Interventions: Biological: Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine;   Biological: Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine
19 Completed Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: Haemophilus influenzae type b- and meningococcal serogroup C (vaccine);   Biological: Infanrix Penta;   Biological: Infanrix hexa;   Biological: Neis-Vac-C
20 Completed Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Intervention: Biological: Haemophilus influenzae type b- and meningococcal (vaccine)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.